Clinical Trial Highlights

• Downregulation of ERCC1 Boosts Efficacy of Platinum-Based NSCLC Chemotherapy
• Paclitaxel plus Bevacizumab is a Feasible Option for Chemoresistant SCLC
• No Significant Difference in Treatment versus Supportive Care in Stage IV NSCLC
• Benefit and Tolerance to Induction Therapy in Elderly Patients with Locally Advanced NSCLC
• Brain Metastases Safely Treated with WBRT after Bevacizumab and Chemotherapy in NSCLC
• Progression-Free Survival Not Improved with Cabazitaxel versus Topotecan in Refractory SCLC
• Randomized, Prospective Trial of Customized Neoadjuvant versus Standard Chemotherapy Gets Underway